These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36924087)

  • 1. Clinical efficacy of anti-SARS-CoV-2 monoclonal antibodies in preventing hospitalisation and mortality among patients infected with Omicron variants: A systematic review and meta-analysis.
    Miljanovic D; Cirkovic A; Lazarevic I; Knezevic A; Cupic M; Banko A
    Rev Med Virol; 2023 Jul; 33(4):e2439. PubMed ID: 36924087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
    Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW
    Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data.
    Russo A; Grimaldi P; Pisaturo M; Onorato L; Coppola N
    Front Immunol; 2024; 15():1295029. PubMed ID: 38352882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
    Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
    Elife; 2022 Nov; 11():. PubMed ID: 36413383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
    Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
    J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3.
    Huang M; Wu L; Zheng A; Xie Y; He Q; Rong X; Han P; Du P; Han P; Zhang Z; Zhao R; Jia Y; Li L; Bai B; Hu Z; Hu S; Niu S; Hu Y; Liu H; Liu B; Cui K; Li W; Zhao X; Liu K; Qi J; Wang Q; Gao GF
    Immunity; 2022 Aug; 55(8):1501-1514.e3. PubMed ID: 35777362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
    Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
    J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real world effectiveness of sotrovimab in preventing COVID-19-related hospitalisation or death in patients infected with Omicron BA.2.
    Behzad A; Mohamed A; Ali A; Niinuma S; Butler AE; Alqahtani M
    J Infect Public Health; 2024 Feb; 17(2):315-320. PubMed ID: 38160562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.
    Patel V; Levick B; Boult S; Gibbons DC; Drysdale M; Lloyd EJ; Singh M; Birch HJ
    BMC Infect Dis; 2024 Apr; 24(1):428. PubMed ID: 38649824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab.
    Passariello M; Ferrucci V; Sasso E; Manna L; Lembo RR; Pascarella S; Fusco G; Zambrano N; Zollo M; De Lorenzo C
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase.
    Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Molina KC; Peers JL; Russell S; Wynia MK; Ginde AA
    Int J Infect Dis; 2023 Mar; 128():310-317. PubMed ID: 36229005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
    Bruel T; Stéfic K; Nguyen Y; Toniutti D; Staropoli I; Porrot F; Guivel-Benhassine F; Bolland WH; Planas D; Hadjadj J; Handala L; Planchais C; Prot M; Simon-Lorière E; André E; Baele G; Cuypers L; Mouthon L; Mouquet H; Buchrieser J; Sève A; Prazuck T; Maes P; Terrier B; Hocqueloux L; Schwartz O
    Cell Rep Med; 2022 Dec; 3(12):100850. PubMed ID: 36450283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium.
    Drysdale M; Hautekiet T; Singh M; Hautekiet J; Ludikhuyze L; Patel V; Gibbons DC; De Roeck D; Colpaert K; Lloyd EJ; Van Braeckel E
    Acta Clin Belg; 2024 Jun; 79(3):174-183. PubMed ID: 39081095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
    Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
    Hirsch C; Park YS; Piechotta V; Chai KL; Estcourt LJ; Monsef I; Salomon S; Wood EM; So-Osman C; McQuilten Z; Spinner CD; Malin JJ; Stegemann M; Skoetz N; Kreuzberger N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD014945. PubMed ID: 35713300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series.
    Cicchitto G; Cardillo L; Sequino D; Sabatini P; Adamo L; Marchitiello R; Viscardi M; Cozzolino L; Cavallera A; Bocchino M; Sanduzzi Zamparelli A; Ferrigno F; de Carlo E; de Martinis C; Fusco G
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants.
    Ju B; Zhang Q; Wang Z; Aw ZQ; Chen P; Zhou B; Wang R; Ge X; Lv Q; Cheng L; Zhang R; Wong YH; Chen H; Wang H; Shan S; Liao X; Shi X; Liu L; Chu JJH; Wang X; Zhang Z; Zhang L
    Nat Immunol; 2023 Apr; 24(4):690-699. PubMed ID: 36914890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.
    Huygens S; GeurtsvanKessel C; Gharbharan A; Bogers S; Worp N; Boter M; Bax HI; Kampschreur LM; Hassing RJ; Fiets RB; Levenga H; Afonso PM; Koopmans M; Rijnders BJA; Oude Munnink BB
    Clin Infect Dis; 2024 Jun; 78(6):1514-1521. PubMed ID: 38445721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review.
    Drysdale M; Gibbons DC; Singh M; Rolland C; Lavoie L; Skingsley A; Lloyd EJ
    Infection; 2024 Feb; 52(1):1-17. PubMed ID: 37776474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.